Abstract: Objective To explore the relationship between the changes of inflammation-associated factors, hypersensitive C-reactive protein (hs-CRP), WBC, procalcitonin (PCT), and the mycoplasma pneumonia (MPP) combined with systemic inflammatory response syndrome (SIRS) in children. To clarify the significance of clinical condition evaluation and therapeutic effect assesment. Methods A total of 104 children with Mycoplasma pneumoniae pneumonia, from January 2016 to December 2017, at Bengbu First People's Hospital were selected, 52 cases with concomitant SIRS and 52 cases without SIRS. The 52 cases with concomitant SIRS were then divided into severe group (26 cases) and mild group (26 cases) according to the severity of the disease. The levels of hs-CRP, WBC, and PCT in all cases were detected. Results Compared to the data of before the treatment, hs-CRP (P<0.001), PCT (P=0.007), and WBC (P<0.001) were decreased after treatment in the group with concomitant SIRS, and the difference was statistically significant. However, in the group without concomitant SIRS, only PCT (P=0.008) was decreased compared to the data of before the treatment, and the difference was statistically significant. After treatment in severe groups, hs-CRP (P<0.001), PCT (P=0.007), and WBC (P<0.001) were all decreased compared to the data of before the treatment, and the difference was statistically significant. After treatment in mild groups, hs-CRP (P=0.002) and WBC (P<0.001) were decreased, and the difference was statistically significant. In the group with concomitant SIRS, the application rate of third generation cephalosporin and glucocorticoid in severe group (69.2%, 76.9%) was higher than that in mild group (30.8%, 38.5%), and the difference was statistically significant (all P<0.05). Conclusion The detection of hs-CRP, PCT, and WBC in children with Mycoplasma pneumonia combined with systemic inflammatory response syndrome could help determine the severity, therapeutic efficacy, and prognosis of the disease.